> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Stanford Roadmap Calls for 12 FDA Reforms to Speed Drug Development
- URL: https://www.fdaweb.com/stanford-roadmap-calls-for-12-fda-reforms-to-speed-drug-development/
- Published: 2026-10-08T01:24:00.000Z
- Updated: 2026-10-08T01:24:24.000Z
- Author: David McFarland
- Tags: Drugs

A new Stanford Biodesign policy paper is calling for a dozen bipartisan FDA reforms aimed at accelerating clinical trials and drug reviews, including allowing some lower-risk Phase 1 trials to begin without waiting for prior FDA approval and expanding rolling review of marketing applications.

The paper, [*Roadmap for FDA Modernization: 12 Bipartisan Ideas to Help Patients and Strengthen American Leadership*](https://biodesign.stanford.edu/content/dam/sm/biodesign/documents/programs/policy-program/StanfordBiodesign-Roadmap-for-FDA-Modernization.pdf?ref=fdaweb.com), argues that outdated regulatory requirements are pushing early-stage research to countries including China and Australia and delaying development of therapies for rare and rapidly progressing diseases.

Among its most significant recommendations is a voluntary “clinical trial notification” pathway modeled on Australia's system. Under the proposal, an institutional review board would conduct the front-line review of qualifying lower-risk Phase 1 trials, while sponsors would notify FDA rather than wait for agency approval. The authors estimate that trials could begin in six to 10 weeks rather than the three to six months it takes currently. FDA would retain authority to impose clinical holds, inspect trials, and enforce regulatory requirements.

Other recommendations include clearer Phase 1 chemistry, manufacturing and controls requirements; a formal pathway for qualifying new approach methodologies, including AI-enabled tools; greater flexibility for evolving clinical trial endpoints; and qualification of natural-history datasets for use as external controls in rare-disease trials.

The roadmap also proposes expanded use of platform data for individualized therapies, a mechanism for FDA to share lessons learned across development programs, and a broader rolling or modular review that would allow sponsors to submit completed portions of marketing applications before the entire application is ready.

Another proposal would seek greater consistency in complete response letters by preventing FDA from raising new effectiveness objections in subsequent review cycles based on the same clinical data unless new information emerges. The authors also recommend agreements allowing FDA to rely on portions of reviews conducted by trusted foreign regulators and making the Rare Pediatric Disease Priority Review Voucher program permanent.

The authors argue that the proposals could reduce development costs and accelerate access without changing FDA's statutory standards for safety and effectiveness. Some could be implemented by FDA under existing authority, while others would require congressional action.